Understand how Omico’s prospectively consented, integrated dataset can support decision making across the precision oncology lifecycle—from strategy and trial design to market access.

Access Omico’s biospecimens linked to clinical and genomic data to support translational research, biomarker discovery and academic collaboration.

“Precision oncology is evolving in real time, and to guide it responsibly we need data that reflects real patients and real care. High-quality real-world data allows us to move beyond assumption—giving decision-makers the evidence they need to act with greater clarity and confidence as the science advances.”

“The first real sense of excitement and hope I felt after starting conventional treatment for my cholangiocarcinoma came when my oncologist asked if I would participate in Omico’s MoST study, which included genomic profiling.

As a lung cancer nurse, I knew exactly what this meant because we recruited patients to the study through our lung cancer MDT meetings. I also understood what it could potentially mean for me if my cancer carried a targetable mutation.

New treatment options could open up if a targetable mutation was identified. As it turned out, one was found, and I was eligible for a clinical trial that I successfully participated in—helping me achieve outcomes beyond my initial prognosis.

It also feels meaningful to know that my data, together with that of other participants, may help advance research and create better options and outcomes for people diagnosed in the future.

If my experience can help make a difference for someone else, that is incredibly important to me.”